AstraZeneca, Ionis' heart drug fails in major ATTR trial

AstraZeneca and Ionis' heart drug, eplontersen (Wainua), failed to meet its primary endpoint in a Phase 3 trial for ATTR-CM, a type of heart disease. The trial, dubbed CARDIO-TTRansform, did not show a statistically significant benefit in reducing cardiovascular death or hospitalizations compared to placebo. This marks a significant setback in a competitive market for treating this rare, progressive condition.